IMMX — Immix Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1873835 ·
Last close
$13.61
Market Cap
$968.90M
52W High
$13.80
52W Low
$7.65
ADV30
1,612,808
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,456,343 | -11,557,002 | 239,108,896 | 225,491,985 | 10,192,343 |
| Mar 2026 | 0 | — | -10,803,855 | -10,086,687 | 95,816,057 | 79,250,163 | 11,452,001 |
| Dec 2025 | 0 | — | -10,893,276 | -10,687,830 | 104,840,341 | 93,928,566 | 11,044,171 |
| Sep 2025 | 0 | — | -7,662,509 | -7,585,692 | 20,080,604 | 15,947,308 | 11,815,634 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-32,072,357
Investing CF
$-11,946,908
Financing CF
$107,349,298
CapEx
$-697,698
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-114,549,971
Inventory
—
Receivables
$0
ST Investments
$11,328,999
EBIT TTM
$-36,077,345
Pretax Income TTM
$-34,954,870
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -29,956,415 | -29,438,613 | 104,840,341 | 11,044,171 | — | -23,930,304 |
| Dec 2024 | 0 | -22,674,680 | -21,613,376 | 22,947,872 | 9,696,669 | — | -14,595,102 |
| Dec 2023 | 0 | -16,141,113 | -15,426,048 | 19,925,160 | 3,721,783 | — | -11,371,438 |
| Dec 2022 | 0 | -8,218,948 | -8,229,713 | 14,908,101 | 1,748,296 | — | -7,408,303 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.90
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $13.61 · call volume: 181 · put volume: 36Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARDX | ARDELYX, INC. | $965.62M | $3.74 | — |
| GERN | GERON CORP | $976.56M | $1.52 | — |
| PCRX | Pacira BioSciences, Inc. | $978.19M | $24.86 | — |
| ANNX | Annexon, Inc. | $959.27M | $5.06 | — |
| DSGN | Design Therapeutics, Inc. | $953.12M | $15.23 | — |
News headlines (Yahoo Finance, 1h cache)
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
2026-07-21 21:17 · Yahoo
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
2026-06-18 13:55 · Yahoo
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
2026-05-27 13:55 · Yahoo
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
2026-05-22 21:15 · Yahoo
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
2026-05-21 10:30 · Yahoo
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
2026-05-21 10:00 · Yahoo
Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?
2026-05-05 17:05 · Yahoo
We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth
2026-05-05 12:52 · Yahoo
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
2026-04-09 12:45 · Yahoo
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
2026-03-30 12:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.